Page last updated: 2024-12-08

bis(2,4,4-trimethylpentyl)dithiophosphinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bis(2,4,4-trimethylpentyl)dithiophosphinic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID163778
SCHEMBL ID662002
SCHEMBL ID13388572
MeSH IDM0501943

Synonyms (13)

Synonym
bis(2,4,4-trimethylpentyl)dithiophosphinic acid
diisooctyldithiophosphinic acid, technical, ~85% (t)
107667-02-7
phophinodithioic acid, bis(2,4,4-trimethylpentyl)-
ec 420-160-9
bis(2,4,4-trimethylpentyl)dithiophosphonic acid
phosphinodithioic acid, bis(2,4,4-trimethylpentyl)-
phosphinodithioic acid,p,p-bis(2,4,4-trimethylpentyl)-
SCHEMBL662002
SCHEMBL13388572
sulfanyl-sulfanylidene-bis(2,4,4-trimethylpentyl)-lambda5-phosphane
DTXSID20869479
bis(2,4,4-trimethylpentyl)phosphinodithioic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (55.56)29.6817
2010's3 (33.33)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.40 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]